【摘要】 目的 探讨阿立哌唑治疗精神分裂症的疗效及安全性。 方法 将120例精神分裂症患者随机分为两组各60例，研究组给予阿立哌唑治疗，对照组给予利培酮治疗，采用简明精神病评定量表及副作用量表评定临床疗效和不良反应。 结果 研究组有效率93.33%，显效率90%；对照组有效率98.33%，显效率96.67%。两组差异均无显著性(P>0.05)。BPRS评分治疗第1w末两组均较治疗前明显降低(P<0.001)，随着治疗时间的延长均进一步降低；两组间同期评分比较均无显著性差异(P>0.05)。研究组不良反应总发生率低于对照组。 结论 阿立哌唑治疗精神分裂症疗效显著、依从性好、安全性高，可在临床进一步推广应用。

    【关键词】 精神分裂症；阿立哌唑；利培酮

    A controlled study of aripiprazole and risperidone in the treatment of schizophrenia

    Wang Dongping, Li Yuchun, Feng Yanguo, et al

    (The Second Affiliated Hospital of Xinxiang Medical College , 453002,Henan,China)

    【Abstract】 Objective To explore efficacy and safety of aripiprazole in the treatment of schizophrenia. Methods 120 schizophrenics were randomly assigned to research(n=60, took aripiprazole) and control group(n=60, did risperidone). Clinical efficacy were assessed with the Brief Psychiatric Rating Scale(BRPS) and side effects with the Treatment Emergent Symptom Scale(TESS). Results In the research group, effective and effectual rates were 93.33% and 90% respectively and in the control group 98.33% and 96.67%, which showed no significant difference(P>0.05). At the end of the 1st week, the BRPS scores of both groups were significantly lower than that of pretreatment(P<0.01); at the same time there was no significant difference in the BRPS scores(P>0.05). The total incidence of side effects was lower in the research than in the control group. Conclusion Aripiprazole has significant efficacy, well compliance and higher safety in the treatment of schizophrenia. ......